5th Advancing Immunomodulation Meeting

29 September 2026

London, UK

Tuesday, 29th September 2026

Moderator: Prof Stephanie Lee, USA

16:00 – 16:15

Welcome & introduction

Prof Stephanie Lee, USA

16:15 – 17:00

NIH 2025 chronic GvHD consensus: What are the unmet clinical needs?

Prof Stephanie Lee, USA

Cellular drivers of cGvHD: Which cells matter, when?

17:00 – 17:15

Antigen presenting cells and innate immunity in cGvHD: From initiators to sustainers of disease

Prof Andrew Gennery, UK

17:15 – 17:30

B cells in cGvHD: Pathogenic drivers and therapeutic targets

Prof Stefanie Sarantopoulos, USA

17:30 – 18:00

Coffee break

18:00 – 18:15

Regulatory T cells and immune tolerance in cGvHD: Why don’t we achieve durable control?

Prof Amandeep Salhotra, USA

18:15 – 18:30

Myeloid cells in cGvHD: Late entrants that rewrote the story

Speaker TBC

18:30 – 19:00

From cellular dysregulation to clinical disease: The pathophysiology of cGvHD

Prof Robert Zeiser, Germany

19:00 – 19:30

Panel discussion

All faculty

20:00

Dinner

Wednesday, 20th September 2026

How to improve success in treating GvHD patients

09:00 – 09:30

Translating biology into clinical signals: What should we measure in cGvHD?

Speaker TBC

09:30 – 09:45

Cellular biomarkers in cGvHD: Promise, pitfalls, and practicality

Prof Kirk Schultz, Canada

09:45 – 10:00

Tissue biomarkers in cGvHD: Are we measuring the right organ at the right time?

Prof Rachel Rosenstein, USA

10:00 – 10:15

Plasma protein biomarkers in cGvHD: From discovery to clinical relevance

Prof Sophie Paczesny, USA

10:15 – 10:30

Q&A biomarkers

10:30 – 10:45

Composite endpoints and PROs in cGvHD: Are we measuring what matters?

Dr Francesca Kinsella, UK

10:45 – 11:15

Coffee break

Navigating the patient journey

11:15 – 11:45

Achieving the clinical goal for immunotolerance

Prof Anna Reed, UK

How I treat cGvHD

11:45 – 12:15

The role of ECP in treating steroid-refractory cGvHD

Prof Andrea Bacigalupo, Italy

12:15 – 12:45

Strategic use of ECP in modern cGvHD management

Prof Hildegard Greinix, Austria

12:45 – 13:15

Panel discussion

All faculty

13:15

Lunch

ECP: Extracorporeal Photopheresis, cGvHD: Chronic Graft vs Host Disease, GvHD: Graft vs Host Disease, NIH: National Institutes of Health, PROs: Patient-Reported Outcomes

All speakers are subject to contract.

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

5th Advancing Immunomodulation Meeting

Tuesday, 29th September 2026

Wednesday, 20th September 2026

Brought to you by the Therakos Institute

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS